Welcome!

Artificial Intelligence Authors: Yeshim Deniz, William Schmarzo, Liz McMillan, Pat Romanski, Elizabeth White

News Feed Item

Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.

Adaptive will accept clinical samples in its CLIA certified, state-of-the-art immune repertoire sequencing laboratory in 2013

SEATTLE, Dec. 6, 2012 /PRNewswire/ -- Adaptive Biotechnologies, a leading provider of next-generation sequencing assays for the adaptive immune system, today introduced clonoSEQ, a clinical assay to measure minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests.

clonoSEQ will be available for widespread clinical use by mid-2013.

"This new approach of using high throughput sequencing to detect and track residual disease is an important advance for clinical hematologists and their patients," said Chad Robins, CEO of Adaptive Biotechnologies. "This will help doctors more effectively determine effectiveness of treatments, monitor patient remission status, and personalize future treatments."

The launch of clonoSEQ follows a key publication in Science Translational Medicine from May 2012, in collaboration with Fred Huchinson Cancer Research Center and the University of Washington Department of Laboratory Medicine, demonstrating that clonoSEQ detected minimal residual disease in nearly twice the number of patients with T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL) than flow cytometry.

Select highlights of this research will be presented in December 2012, at the Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

Minimal residual disease is the name given to small numbers of leukemic cells that remain in the patient during treatment, or after treatment when the patient is in remission. The number of these residual cells may be, in some cases, correlated with the risk of relapse. Knowledge of MRD can influence clinical care and increase cure rates.

Adaptive has extensive experience applying its MRD assay in the research setting with academic centers worldwide, and has instituted pioneering quality control measures to markedly improve the accuracy and sensitivity of MRD testing as well as simplify data reporting to make comprehension easier and quicker for hematologists. These enhancements include:

  • Developing a proprietary set of immune receptor templates to eliminate PCR amplification bias
  • Instituting a systematic chain of custody to handle customer samples
  • Building a bioinformatics platform to enable the measurement of MRD as a ratio of the malignant clone to the total number of nucleated cells in a blood sample as well as to the lineage-related cells

Future plans for clonoSEQ include the development and distribution of a proprietary kit that would allow for the assay to be performed in selected point-of-need clinical pathology laboratories. 

"Without controls in place as reliable as the set of immune receptor templates we have developed to eliminate any PCR bias, standardization of a kit would be quite difficult," explained Adaptive co-founder Dr. Harlan Robins

Adaptive has several other assays being prepped for clinical use in oncology/hematology, immunology, and infectious diseases.

The company remains committed to expanding the use of its platforms as diagnostic tools in clinical trials and as fee-for-service research whereby academic and industry collaborators can incorporate studies of B and T-cell immune repertoire status into their studies. 

About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry.  Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013.  Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system's defense against disease – with unprecedented depth and specificity.  In 2013, the company will introduce clonoSEQ (http://www.clonoseq.com),a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. All of Adaptive Biotechnologies' assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.

SOURCE Adaptive Biotechnologies Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
Apps and devices shouldn't stop working when there's limited or no network connectivity. Learn how to bring data stored in a cloud database to the edge of the network (and back again) whenever an Internet connection is available. In his session at 17th Cloud Expo, Ben Perlmutter, a Sales Engineer with IBM Cloudant, demonstrated techniques for replicating cloud databases with devices in order to build offline-first mobile or Internet of Things (IoT) apps that can provide a better, faster user e...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
Disruption, Innovation, Artificial Intelligence and Machine Learning, Leadership and Management hear these words all day every day... lofty goals but how do we make it real? Add to that, that simply put, people don't like change. But what if we could implement and utilize these enterprise tools in a fast and "Non-Disruptive" way, enabling us to glean insights about our business, identify and reduce exposure, risk and liability, and secure business continuity?
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
To Really Work for Enterprises, MultiCloud Adoption Requires Far Better and Inclusive Cloud Monitoring and Cost Management … But How? Overwhelmingly, even as enterprises have adopted cloud computing and are expanding to multi-cloud computing, IT leaders remain concerned about how to monitor, manage and control costs across hybrid and multi-cloud deployments. It’s clear that traditional IT monitoring and management approaches, designed after all for on-premises data centers, are falling short in ...
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"MobiDev is a Ukraine-based software development company. We do mobile development, and we're specialists in that. But we do full stack software development for entrepreneurs, for emerging companies, and for enterprise ventures," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...